Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Frovatriptan · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Frovatriptan 2.5 mg | EXPERIMENTAL | Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6. |
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Frovatriptan 2.5mg QD | DRUG | - |
| Frovatriptan 2.5 mg BID | DRUG | - |
| placebo | DRUG | - |
| Frovatriptan 2.5 mg | DRUG | - |
| Frovatriptan | DRUG | 2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache |
Inclusion Criteria: * Pre-menopausal females diagnosed as suffering from MRM aged 15 years and over, that fit the criteria for 'difficult to treat'
Frovatriptan is a small molecule drug used for the prevention of menstrually associated migraine and migraine. It is being developed by BrainsWay Ltd. (BWAY) and is currently in Phase 3 clinical development, though the listed trials are all completed.
Frovatriptan is a triptan that works by binding to serotonin receptors, specifically the 5-HT1B and 5-HT1D receptors, to constrict cranial blood vessels and inhibit the release of pro-inflammatory neuropeptides, thereby relieving migraine symptoms.
Frovatriptan is being developed by BrainsWay Ltd., a company traded on the stock exchange under the ticker BWAY. The drug is currently in Phase 3 clinical development for the prevention of menstrually associated migraine and migraine.
Frovatriptan is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All three Phase 3 trials listed have been completed, with a total enrollment of 1,050 participants.
Frovatriptan has been studied in three completed Phase 3 trials: NCT00475514, NCT00644033, and NCT01035983. These trials evaluated the efficacy and safety of frovatriptan for the prevention of menstrual migraine and menstrually associated migraine, enrolling a total of 1,050 female participants.
Frovatriptan is a triptan class medication, similar to other drugs in its class, but it is a distinct chemical entity. It is specifically being studied for the intermittent prevention of menstrually associated migraine, a niche indication within the broader migraine treatment landscape.